Rui Fang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rui Fang has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Dahua Wu
Department of Neurology, Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine (The Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine), Changsha, China
3 shared publications - Le Xie
Department of Neurology, Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine (The Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine), Changsha, China
3 shared publications Baisheng Xie
Hangzhou Normal Univ, Sch Med, Hangzhou 310018, Zhejiang, Peoples R China
2 shared publicationsChenyang Ma
Zhejiang Chinese Med Univ, Clin Med Coll 3, Hangzhou 310053, Zhejiang, Peoples R China
2 shared publicationsHaicheng Han
Hangzhou Normal Univ, Sch Med, Hangzhou 310018, Zhejiang, Peoples R China
2 shared publications- Jie Tang
Graduate School of Hunan University of Chinese Medicine, Changsha, CN
2 shared publications
Latest Publications
- Open Access
- 8 December 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e77661
Real-World Efficacy and Safety of Zishenyizhi Pill for Cognitive Impairment Associated With Cerebral Small Vessel Disease: Protocol for a Multicenter Prospective Observational Study
Background: Cerebral small vessel disease (CSVD) is a leading cause of vascular cognitive impairment, contributing to 36% to 67% of vascular dementia cases. Current therapies, primarily cholinesterase inhibitors, offer limited efficacy and significant adverse effects. Traditional Chinese medicine, particularly the zishenyizhi pill, which is a multiherb formulation targeting yin deficiency and blood stasis, has shown promise in preliminary studies but lacks robust clinical validation. Objective: We designed this study to evaluate the real-world efficacy and safety of zishenyizhi pill combined with conventional Western therapy for CSVD-related cognitive impairment. Methods: This multicenter, prospective, nonrandomized controlled trial enrolled 246 patients from 4 institutions in Hunan province, China. Participants were stratified into 2 groups: the intervention group received zishenyizhi pill plus standard Western therapy, whereas the control group received conventional integrated Chinese-Western therapy. Cognitive outcomes (Montreal Cognitive Assessment, Mini-Mental State Examination, Vascular Dementia Assessment Scale cognitive subscale, and Trail Making Test parts A and B), traditional Chinese medicine syndrome scores, and safety parameters were assessed over 12 weeks. Results: Participant recruitment is scheduled to commence in April 2025, with an anticipated enrollment of 246 participants by December 2026. At present, patient recruitment is underway, and preliminary analysis of medical record data is being conducted. Final data collection is expected to conclude by April 2027, with results projected for publication in September 2027. Conclusions: The anticipated findings suggest that zishenyizhi pill may improve multiple cognitive domains in patients with cognitive impairment associated with CSVD while demonstrating a favorable safety profile. If validated, zishenyizhi pill could serve as a safe and effective adjunctive therapy for CSVD-related cognitive dysfunction. Trial Registration: International Traditional Medicine Clinical Trial Registry ITMCTR2025000553; https://itmctr.ccebtcm.org.cn/mgt/project/view/-4790836881284495026 International Registered Report Identifier (IRRID): DERR1-10.2196/77661
- 8 December 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e77661
Open AccessReal-World Efficacy and Safety of Zishenyizhi Pill for Cognitive Impairment Associated With Cerebral Small Vessel Disease: Protocol for a Multicenter Prospective Observational Study
Background: Cerebral small vessel disease (CSVD) is a leading cause of vascular cognitive impairment, contributing to 36% to 67% of vascular dementia cases. Current therapies, primarily cholinesterase inhibitors, offer limited efficacy and significant adverse effects. Traditional Chinese medicine, particularly the zishenyizhi pill, which is a multiherb formulation targeting yin deficiency and blood stasis, has shown promise in preliminary studies but lacks robust clinical validation. Objective: We designed this study to evaluate the real-world efficacy and safety of zishenyizhi pill combined with conventional Western therapy for CSVD-related cognitive impairment. Methods: This multicenter, prospective, nonrandomized controlled trial enrolled 246 patients from 4 institutions in Hunan province, China. Participants were stratified into 2 groups: the intervention group received zishenyizhi pill plus standard Western therapy, whereas the control group received conventional integrated Chinese-Western therapy. Cognitive outcomes (Montreal Cognitive Assessment, Mini-Mental State Examination, Vascular Dementia Assessment Scale cognitive subscale, and Trail Making Test parts A and B), traditional Chinese medicine syndrome scores, and safety parameters were assessed over 12 weeks. Results: Participant recruitment is scheduled to commence in April 2025, with an anticipated enrollment of 246 participants by December 2026. At present, patient recruitment is underway, and preliminary analysis of medical record data is being conducted. Final data collection is expected to conclude by April 2027, with results projected for publication in September 2027. Conclusions: The anticipated findings suggest that zishenyizhi pill may improve multiple cognitive domains in patients with cognitive impairment associated with CSVD while demonstrating a favorable safety profile. If validated, zishenyizhi pill could serve as a safe and effective adjunctive therapy for CSVD-related cognitive dysfunction. Trial Registration: International Traditional Medicine Clinical Trial Registry ITMCTR2025000553; https://itmctr.ccebtcm.org.cn/mgt/project/view/-4790836881284495026 International Registered Report Identifier (IRRID): DERR1-10.2196/77661
- Open Access
- 17 May 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Real-World Efficacy and Safety of Zishenyizhi Pill for Cognitive Impairment Associated With Cerebral Small Vessel Disease: Protocol for a Multicenter Prospective Observational Study (Preprint)
BACKGROUND Cerebral small vessel disease (CSVD) is a leading cause of vascular cognitive impairment, contributing to 36% to 67% of vascular dementia cases. Current therapies, primarily cholinesterase inhibitors, offer limited efficacy and significant adverse effects. Traditional Chinese medicine, particularly the zishenyizhi pill, which is a multiherb formulation targeting yin deficiency and blood stasis, has shown promise in preliminary studies but lacks robust clinical validation. OBJECTIVE We designed this study to evaluate the real-world efficacy and safety of zishenyizhi pill combined with conventional Western therapy for CSVD-related cognitive impairment. METHODS This multicenter, prospective, nonrandomized controlled trial enrolled 246 patients from 4 institutions in Hunan province, China. Participants were stratified into 2 groups: the intervention group received zishenyizhi pill plus standard Western therapy, whereas the control group received conventional integrated Chinese-Western therapy. Cognitive outcomes (Montreal Cognitive Assessment, Mini-Mental State Examination, Vascular Dementia Assessment Scale cognitive subscale, and Trail Making Test parts A and B), traditional Chinese medicine syndrome scores, and safety parameters were assessed over 12 weeks. RESULTS Participant recruitment is scheduled to commence in April 2025, with an anticipated enrollment of 246 participants by December 2026. At present, patient recruitment is underway, and preliminary analysis of medical record data is being conducted. Final data collection is expected to conclude by April 2027, with results projected for publication in September 2027. CONCLUSIONS The anticipated findings suggest that zishenyizhi pill may improve multiple cognitive domains in patients with cognitive impairment associated with CSVD while demonstrating a favorable safety profile. If validated, zishenyizhi pill could serve as a safe and effective adjunctive therapy for CSVD-related cognitive dysfunction. CLINICALTRIAL International Traditional Medicine Clinical Trial Registry ITMCTR2025000553; https://itmctr.ccebtcm.org.cn/mgt/project/view/-4790836881284495026 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/77661
- 17 May 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessReal-World Efficacy and Safety of Zishenyizhi Pill for Cognitive Impairment Associated With Cerebral Small Vessel Disease: Protocol for a Multicenter Prospective Observational Study (Preprint)
BACKGROUND Cerebral small vessel disease (CSVD) is a leading cause of vascular cognitive impairment, contributing to 36% to 67% of vascular dementia cases. Current therapies, primarily cholinesterase inhibitors, offer limited efficacy and significant adverse effects. Traditional Chinese medicine, particularly the zishenyizhi pill, which is a multiherb formulation targeting yin deficiency and blood stasis, has shown promise in preliminary studies but lacks robust clinical validation. OBJECTIVE We designed this study to evaluate the real-world efficacy and safety of zishenyizhi pill combined with conventional Western therapy for CSVD-related cognitive impairment. METHODS This multicenter, prospective, nonrandomized controlled trial enrolled 246 patients from 4 institutions in Hunan province, China. Participants were stratified into 2 groups: the intervention group received zishenyizhi pill plus standard Western therapy, whereas the control group received conventional integrated Chinese-Western therapy. Cognitive outcomes (Montreal Cognitive Assessment, Mini-Mental State Examination, Vascular Dementia Assessment Scale cognitive subscale, and Trail Making Test parts A and B), traditional Chinese medicine syndrome scores, and safety parameters were assessed over 12 weeks. RESULTS Participant recruitment is scheduled to commence in April 2025, with an anticipated enrollment of 246 participants by December 2026. At present, patient recruitment is underway, and preliminary analysis of medical record data is being conducted. Final data collection is expected to conclude by April 2027, with results projected for publication in September 2027. CONCLUSIONS The anticipated findings suggest that zishenyizhi pill may improve multiple cognitive domains in patients with cognitive impairment associated with CSVD while demonstrating a favorable safety profile. If validated, zishenyizhi pill could serve as a safe and effective adjunctive therapy for CSVD-related cognitive dysfunction. CLINICALTRIAL International Traditional Medicine Clinical Trial Registry ITMCTR2025000553; https://itmctr.ccebtcm.org.cn/mgt/project/view/-4790836881284495026 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/77661
- Open Access
- 17 August 2022
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 29, 100975
A randomized double-blind controlled study protocol on the efficacy and safety of Sangdantongluo granule in the treatment of post-stroke spasticity
- 17 August 2022
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 29, 100975
Open AccessA randomized double-blind controlled study protocol on the efficacy and safety of Sangdantongluo granule in the treatment of post-stroke spasticity
- Open Access
- 3 December 2019
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2019, 1-12
Traditional Chinese Medicine-Guided Dietary Intervention for Male Youth Undergoing Drug Detoxification: A Randomized Controlled Trial
Objective. The aim of this study was to evaluate the effectiveness of traditional Chinese medicine- (TCM-) guided dietary interventions in improving yang-qi deficiency and yin-blood deficiency TCM syndromes according to the principles of TCM syndrome differentiation theory in male youths undergoing drug detoxification during the rehabilitation period who stayed in a compulsory isolation detoxification center. Methods. Male youths undergoing drug detoxification who met the criteria to be included in the study were randomly divided into the intervention group (n = 62) and the control group (n = 61) according to a random number table in a 1 : 1 ratio. The intervention group received a TCM-guided diet, and the control group received routine food support. Over an intervention period of 3 months, we observed changes in the TCM syndrome element scores in the two groups before and after intervention. Results. After 3 months, the qi deficiency, yin deficiency, blood deficiency, and yin-blood deficiency syndrome in the intervention group improved significantly ( values 0.009, 0.000, 0.005, and 0.001, respectively). In the control group, yang deficiency, qi deficiency, and yang-qi deficiency syndromes worsened significantly ( values 0.003, 0.032, and 0.009, respectively). The differences (post-pre) in yang deficiency, qi deficiency, yang-qi deficiency, yin deficiency, blood deficiency, and yin-blood deficiency syndromes between the two groups were statistically significant ( values 0.003, 0.003, 0.003, 0.001, 0.005, and 0.002, respectively). Conclusion. A TCM-guided diet can delay the worsening of yang-qi deficiency syndrome symptoms and improve yin-blood deficiency syndrome and the prognosis of male youth undergoing drug detoxification during the rehabilitation period.- 3 December 2019
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2019, 1-12
Open AccessTraditional Chinese Medicine-Guided Dietary Intervention for Male Youth Undergoing Drug Detoxification: A Randomized Controlled Trial
Objective. The aim of this study was to evaluate the effectiveness of traditional Chinese medicine- (TCM-) guided dietary interventions in improving yang-qi deficiency and yin-blood deficiency TCM syndromes according to the principles of TCM syndrome differentiation theory in male youths undergoing drug detoxification during the rehabilitation period who stayed in a compulsory isolation detoxification center. Methods. Male youths undergoing drug detoxification who met the criteria to be included in the study were randomly divided into the intervention group (n = 62) and the control group (n = 61) according to a random number table in a 1 : 1 ratio. The intervention group received a TCM-guided diet, and the control group received routine food support. Over an intervention period of 3 months, we observed changes in the TCM syndrome element scores in the two groups before and after intervention. Results. After 3 months, the qi deficiency, yin deficiency, blood deficiency, and yin-blood deficiency syndrome in the intervention group improved significantly ( values 0.009, 0.000, 0.005, and 0.001, respectively). In the control group, yang deficiency, qi deficiency, and yang-qi deficiency syndromes worsened significantly ( values 0.003, 0.032, and 0.009, respectively). The differences (post-pre) in yang deficiency, qi deficiency, yang-qi deficiency, yin deficiency, blood deficiency, and yin-blood deficiency syndromes between the two groups were statistically significant ( values 0.003, 0.003, 0.003, 0.001, 0.005, and 0.002, respectively). Conclusion. A TCM-guided diet can delay the worsening of yang-qi deficiency syndrome symptoms and improve yin-blood deficiency syndrome and the prognosis of male youth undergoing drug detoxification during the rehabilitation period. - 1 May 2019
- Vol. 24 (3) , 918-928
Clinical characteristics on low-dose high-resolution computed tomography and serum tumor markers of malignant pulmonary solid small nodules and postoperative survival analysis
Purpose: To observe the clinical features of low-dose, high-resolution computed tomography (LDCT) and changes in serum tumor markers in malignant pulmonary solid small nodules (MPSSN), and to analyze the difference in survival of patients with malignant and benign PSSN 3 years after surgery. Methods: Patients were enrolled from the thoracic surgery department of three hospitals. According to pathological diagnosis, all patients were divided into the case group (MPSSN, n=157) and the control group (BPSSN, n=75). There were no significant differences in gender, smoking habit, and family disease history. All subjects were subjected to LDCT. Four serum tumor markers (CEA, SCC, NSE, ProGRP) were examined simultaneously. Two independent sample t-tests, Mann-Whitney U rank sum test and Pearson chi-square test were used for comparsions. Two-category logistic regression was performed to analyze LDCT index and serum tumor markers levels of the two groups. ROC curve was used to evaluate the diagnostic sensitivity and specificity of relevant indicators. Kaplan-Meier method, log-rank and generalized Wilcoxon test were used to analyze the survival rate of patients after surgery. Results: In univariate analysis, age, nodule size, bronchial aeration sign, bronchial truncation sign, burr sign, smooth sign and lobulated sign, SCC, NSE, and ProGRP were significantly different between two groups (p <0.05 or 0.01). In the regression analysis, there was a significant correlation between MPSSN and age (X1)[95%CI (1.272, 5.257), p=0.009], nodule size (X2) [95%CI (1.066, 2.746), p=0.04.11, bronchial aeration sign (X3) [95%CI (1.384, 11.425), p=0.010], bronchial truncation sign (X4) [95 %CI (1.269, 13.444), p=0.018) and burr sign (X5) [95%CI (0.054, 0.661), p=0.009] ProGRP (X10) [95%CI (1.302, 2.439), p=0.040]. The stepwise regression equation is Logistic(p)=-3.014+0.950 X1+0.064 X2+1.380 X3+1.419 X4-1.666 X5+0.263 X10. Log-rank and generalized Wilcoxon test analysis showed no difference in survival rate between the two groups (log rank p=0.271, generalized Wilcoxon, p=0.139). Conclusions: The levels of CEA, SCC, NSE and ProGRP in MPSSN were increased; age, nodule size, bronchial aeration sign, bronchial truncation sign and burr sign had predictive value for MPSSN. Patients with PSSN had better survival rates at 3 years after surgery.
- 1 May 2019
- Vol. 24 (3) , 918-928
Clinical characteristics on low-dose high-resolution computed tomography and serum tumor markers of malignant pulmonary solid small nodules and postoperative survival analysis
Purpose: To observe the clinical features of low-dose, high-resolution computed tomography (LDCT) and changes in serum tumor markers in malignant pulmonary solid small nodules (MPSSN), and to analyze the difference in survival of patients with malignant and benign PSSN 3 years after surgery. Methods: Patients were enrolled from the thoracic surgery department of three hospitals. According to pathological diagnosis, all patients were divided into the case group (MPSSN, n=157) and the control group (BPSSN, n=75). There were no significant differences in gender, smoking habit, and family disease history. All subjects were subjected to LDCT. Four serum tumor markers (CEA, SCC, NSE, ProGRP) were examined simultaneously. Two independent sample t-tests, Mann-Whitney U rank sum test and Pearson chi-square test were used for comparsions. Two-category logistic regression was performed to analyze LDCT index and serum tumor markers levels of the two groups. ROC curve was used to evaluate the diagnostic sensitivity and specificity of relevant indicators. Kaplan-Meier method, log-rank and generalized Wilcoxon test were used to analyze the survival rate of patients after surgery. Results: In univariate analysis, age, nodule size, bronchial aeration sign, bronchial truncation sign, burr sign, smooth sign and lobulated sign, SCC, NSE, and ProGRP were significantly different between two groups (p <0.05 or 0.01). In the regression analysis, there was a significant correlation between MPSSN and age (X1)[95%CI (1.272, 5.257), p=0.009], nodule size (X2) [95%CI (1.066, 2.746), p=0.04.11, bronchial aeration sign (X3) [95%CI (1.384, 11.425), p=0.010], bronchial truncation sign (X4) [95 %CI (1.269, 13.444), p=0.018) and burr sign (X5) [95%CI (0.054, 0.661), p=0.009] ProGRP (X10) [95%CI (1.302, 2.439), p=0.040]. The stepwise regression equation is Logistic(p)=-3.014+0.950 X1+0.064 X2+1.380 X3+1.419 X4-1.666 X5+0.263 X10. Log-rank and generalized Wilcoxon test analysis showed no difference in survival rate between the two groups (log rank p=0.271, generalized Wilcoxon, p=0.139). Conclusions: The levels of CEA, SCC, NSE and ProGRP in MPSSN were increased; age, nodule size, bronchial aeration sign, bronchial truncation sign and burr sign had predictive value for MPSSN. Patients with PSSN had better survival rates at 3 years after surgery.
- Open Access
- 18 October 2018
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 16 (6) , 5384-5389
Effect of emodin on chondrocyte viability in an in vitro model of osteoarthritis
Emodin is an anthraquinone isolated from the Chinese herb Radix et Rhizoma Rhei and has been used to treat various diseases for centuries. The aim of the present study was to investigate the effect of emodin on the inflammatory mediators in rat chondrocytes. In the present study, chondrocytes were isolated from rats, cultured and harvested when they reached generation P3. Cells were treated with different doses of emodin (10, 20, and 30 µg/ml) followed by interleukin 1β (IL‑1β, 10 ng/ml). Control cells were either untreated or treated with IL‑1β alone. An enzyme‑linked immunosorbent assay was used to measure levels of nitric oxide (NO) and prostaglandin E2 (PGE2). Reverse transcription‑quantitative polymerase chain was performed to measure levels of matrix metallopeptidase (MMP)‑3 and ‑13 mRNA. The expression of MMP‑3, MMP‑13, extracellular‑signal regulatory kinase (ERK)1/2, phosphorylated ERK1/2 and β‑catenin proteins were detected by western‑blot analysis. The results demonstrated that treatment with emodin treatment reduced the cytotoxicity of IL‑1β and inhibited the expression of NO and PGE2 in rat chondrocytes. Furthermore, emodin inhibited the expression of MMP3 and MMP13, and the phosphorylation of various proteins involved in the ERK and Wnt/β‑catenin pathway. Therefore, emodin is able to promote the proliferation of chondrocytes by inhibiting the ERK and Wnt/β‑catenin pathway and downregulating the expression of a series of inflammatory mediators in chondrocytes.
- 18 October 2018
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 16 (6) , 5384-5389
Open AccessEffect of emodin on chondrocyte viability in an in vitro model of osteoarthritis
Emodin is an anthraquinone isolated from the Chinese herb Radix et Rhizoma Rhei and has been used to treat various diseases for centuries. The aim of the present study was to investigate the effect of emodin on the inflammatory mediators in rat chondrocytes. In the present study, chondrocytes were isolated from rats, cultured and harvested when they reached generation P3. Cells were treated with different doses of emodin (10, 20, and 30 µg/ml) followed by interleukin 1β (IL‑1β, 10 ng/ml). Control cells were either untreated or treated with IL‑1β alone. An enzyme‑linked immunosorbent assay was used to measure levels of nitric oxide (NO) and prostaglandin E2 (PGE2). Reverse transcription‑quantitative polymerase chain was performed to measure levels of matrix metallopeptidase (MMP)‑3 and ‑13 mRNA. The expression of MMP‑3, MMP‑13, extracellular‑signal regulatory kinase (ERK)1/2, phosphorylated ERK1/2 and β‑catenin proteins were detected by western‑blot analysis. The results demonstrated that treatment with emodin treatment reduced the cytotoxicity of IL‑1β and inhibited the expression of NO and PGE2 in rat chondrocytes. Furthermore, emodin inhibited the expression of MMP3 and MMP13, and the phosphorylation of various proteins involved in the ERK and Wnt/β‑catenin pathway. Therefore, emodin is able to promote the proliferation of chondrocytes by inhibiting the ERK and Wnt/β‑catenin pathway and downregulating the expression of a series of inflammatory mediators in chondrocytes.
- 1 August 2018
- Vol. 43 (16) , 3376-3381
[Analysis on medication rules for treatment of dementia by ancient physicians based on data mining methods].
To analyze the medication features and regularity of prescriptions of Chinese medicine in treating patients with dementia based on ancient medical records. In the article, we retrieved the ancient medical records related to the treatment of dementia (from the Han Dynasty to the late Qing period) in Chinese Medical Classics, Chinese Ancient Medical Books and digital library, and then set up a medical records normalized database. The medication features and prescription rules for dementia were analyzed by frequency statistics and association rules (Apriori algorithm, improved mutual information algorithm and complex system entropy clustering). Finally, a total of 156 prescriptions were selected, involving 123 Chinese herbs, with a total frequency of 11 747 for the herbs, and 8 core prescriptions were mined. After the association rules between the frequency and prescriptions for the treatment of dementia were determined, we found that the most commonly used herbs included Fuling (Poria), Yuanzhi (Polygalae Radix), Renshen (Ginseng Radix et Rhizoma), Shichangpu (Acori Tatarinowii Rhizoma), Gancao (Glycyrrhizae Radix et Rhizoma), Danggui (Angelicae Sinensis Radix), Maidong (Ophiopogonis Radix), Baizhu (Bletillae Rhizoma), Dihuang (Rehmanniae Radix) and Ganjiang (Zingiberis Rhizoma); the frequently-used drugs compatibility was mainly for tonifying Qi-blood, regulating Yin and Yang and inducing resuscitation. The drugs were mainly of warm nature and sweet (mild) flavor, and the channel tropism of drugs mainly distributed to the heart, liver, spleen and kidney. The core prescriptions were composed of Renshen (Ginseng Radix et Rhizoma), Fuling (Poria), Yuanzhi (Polygalae Radix), Shichangpu (Acori Tatarinowii Rhizoma), and Baizhu(Bletillae Rhizoma). In conclusion, high frequency herbs and core prescriptions reflect the prescriptions by ancient physicians mainly focus on Qi-replenishing, spleen-invigorating and heart-nourishing, but also reflect the prescription rules of nourishing Yin, enriching blood, eliminating phlegm and warming Yang for the treatment of dementia. The medication features and prescription rules for the treatment of dementia obtained by association rules are useful to guide the clinical practice of Chinese medicine in treatment of dementia.
- 1 August 2018
- Vol. 43 (16) , 3376-3381
[Analysis on medication rules for treatment of dementia by ancient physicians based on data mining methods].
To analyze the medication features and regularity of prescriptions of Chinese medicine in treating patients with dementia based on ancient medical records. In the article, we retrieved the ancient medical records related to the treatment of dementia (from the Han Dynasty to the late Qing period) in Chinese Medical Classics, Chinese Ancient Medical Books and digital library, and then set up a medical records normalized database. The medication features and prescription rules for dementia were analyzed by frequency statistics and association rules (Apriori algorithm, improved mutual information algorithm and complex system entropy clustering). Finally, a total of 156 prescriptions were selected, involving 123 Chinese herbs, with a total frequency of 11 747 for the herbs, and 8 core prescriptions were mined. After the association rules between the frequency and prescriptions for the treatment of dementia were determined, we found that the most commonly used herbs included Fuling (Poria), Yuanzhi (Polygalae Radix), Renshen (Ginseng Radix et Rhizoma), Shichangpu (Acori Tatarinowii Rhizoma), Gancao (Glycyrrhizae Radix et Rhizoma), Danggui (Angelicae Sinensis Radix), Maidong (Ophiopogonis Radix), Baizhu (Bletillae Rhizoma), Dihuang (Rehmanniae Radix) and Ganjiang (Zingiberis Rhizoma); the frequently-used drugs compatibility was mainly for tonifying Qi-blood, regulating Yin and Yang and inducing resuscitation. The drugs were mainly of warm nature and sweet (mild) flavor, and the channel tropism of drugs mainly distributed to the heart, liver, spleen and kidney. The core prescriptions were composed of Renshen (Ginseng Radix et Rhizoma), Fuling (Poria), Yuanzhi (Polygalae Radix), Shichangpu (Acori Tatarinowii Rhizoma), and Baizhu(Bletillae Rhizoma). In conclusion, high frequency herbs and core prescriptions reflect the prescriptions by ancient physicians mainly focus on Qi-replenishing, spleen-invigorating and heart-nourishing, but also reflect the prescription rules of nourishing Yin, enriching blood, eliminating phlegm and warming Yang for the treatment of dementia. The medication features and prescription rules for the treatment of dementia obtained by association rules are useful to guide the clinical practice of Chinese medicine in treatment of dementia.
- Open Access
- 6 June 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 16 (2) , 2483-2489
Analysis of risk factors for stage I lung adenocarcinoma using low‑dose high‑resolution computed tomography
Risk factors for stage I lung adenocarcinoma were analyzed using low‑dose high‑resolution computed tomography (CT). The patients were divided into case group (stage I lung adenocarcinoma patients) and control group (benign pulmonary nodules patients). All patients were subjected to low‑dose high‑resolution CT. Multiple linear regression was performed to analyze the CT imaging features of the two groups. Stage I lung adenocarcinoma patients were significantly associated with nodular site (X3, upper left lobe) [95% CI (1.796, 54.695), p=0.008], nodule type (X4) (p<0.001), nodule size (X5) [95% CI (0.614, 0.803), p<0.001], spicule sign (X7) [95% CI (0.029, 0.580), p=0.008], lobulation sign (X8) [95% CI (0.048, 0.673), p=0.011]. The stepwise regression equation is: Logistic (p) = ‑12.009 + 2.294X3 ‑ 0.327X4 ‑ 0.354X5 ‑ 2.042X7 ‑ 1.713X8. Risk factors of low‑dose and high‑resolution CT imaging for patients with stage I lung adenocarcinoma are nodular site (upper left lobe), nodule type, nodule size, spicule sign, and lobulation sign.
- 6 June 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 16 (2) , 2483-2489
Open AccessAnalysis of risk factors for stage I lung adenocarcinoma using low‑dose high‑resolution computed tomography
Risk factors for stage I lung adenocarcinoma were analyzed using low‑dose high‑resolution computed tomography (CT). The patients were divided into case group (stage I lung adenocarcinoma patients) and control group (benign pulmonary nodules patients). All patients were subjected to low‑dose high‑resolution CT. Multiple linear regression was performed to analyze the CT imaging features of the two groups. Stage I lung adenocarcinoma patients were significantly associated with nodular site (X3, upper left lobe) [95% CI (1.796, 54.695), p=0.008], nodule type (X4) (p<0.001), nodule size (X5) [95% CI (0.614, 0.803), p<0.001], spicule sign (X7) [95% CI (0.029, 0.580), p=0.008], lobulation sign (X8) [95% CI (0.048, 0.673), p=0.011]. The stepwise regression equation is: Logistic (p) = ‑12.009 + 2.294X3 ‑ 0.327X4 ‑ 0.354X5 ‑ 2.042X7 ‑ 1.713X8. Risk factors of low‑dose and high‑resolution CT imaging for patients with stage I lung adenocarcinoma are nodular site (upper left lobe), nodule type, nodule size, spicule sign, and lobulation sign.